Eli Lilly and Company (NYSE:LLY) Stake Increased by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 6.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,225 shares of the company’s stock after buying an additional 585 shares during the period. Stratos Wealth Partners LTD.’s holdings in Eli Lilly and were worth $860,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC increased its stake in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the last quarter. Washington Trust Bank increased its stake in Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the last quarter. Blair William & Co. IL increased its stake in Eli Lilly and by 13.1% in the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock valued at $21,974,000 after buying an additional 30,299 shares during the last quarter. Finally, Bollard Group LLC increased its stake in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the last quarter. 75.59% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Company (NYSE LLY) opened at 77.07 on Friday. The firm has a market cap of $81.31 billion, a price-to-earnings ratio of 33.35 and a beta of 0.34. The stock’s 50 day moving average is $82.39 and its 200-day moving average is $81.90. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm earned $0.86 EPS. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

TRADEMARK VIOLATION NOTICE: “Eli Lilly and Company (NYSE:LLY) Stake Increased by Stratos Wealth Partners LTD.” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2017/08/19/stratos-wealth-partners-ltd-has-860000-stake-in-eli-lilly-and-company-nyselly-updated.html.

Several equities research analysts have recently weighed in on the stock. Berenberg Bank reissued a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet downgraded shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BMO Capital Markets reaffirmed an “underperform” rating and set a $73.00 price objective on shares of Eli Lilly and in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective for the company. in a research report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $88.27.

In related news, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares in the company, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 in the last three months. 0.20% of the stock is owned by insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit